.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, clients along with metastatic stomach lumps that got biomarker-matched treatments based on spreading tumor DNA profiling showed a higher medical benefit than those getting unmatched treatment.